The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial

Martin, Paul; Armstrong, David; Hunt, Richard H.; Yao, Lei; Bukoski, Margaret; White, Robert J.

doi:10.1038/ajg.2010.368

Cited by 36 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RCTs have shown that switching to another PPI was effective in symptom relief in some patients with refractory GORD symptoms and may be cost effective 87 88. A meta-analysis demonstrated a modest 5% relative increase in the probability of healed ERD with esomeprazole compared with other PPI (lansoprazole, omeprazole, pantoprazole) at 8 weeks 89.…”

Section: Resultsmentioning

confidence: 99%

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Fock

Talley

Goh

et al. 2016

Gut

157

214

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Fock

Talley

Goh

et al. 2016

Gut

157

214

View full text Add to dashboard Cite

“…Switching to another PPI is frequently tested by physicians, and though no strong scientific data (neither pharmacological nor clinical) support this strategy, it has proven to be effective in routine clinical practice. To date, two studies, one uncontrolled98 and one randomised,99 favour a switch to esomeprazole when another PPI brand failed. This option could even be cost-effective 99.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

“…To date, two studies, one uncontrolled98 and one randomised,99 favour a switch to esomeprazole when another PPI brand failed. This option could even be cost-effective 99. Doubling the dose of PPI is very common though, again, virtually no data support this strategy.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors

Sifrim¹,

Zerbib

2012

Gut

296

249

View full text Add to dashboard Cite

Approximately a third of patients with suspected gastro-oesophageal reflux disease are resistant or partial responders to proton pump inhibitors (PPIs). Many of these patients do not have gastro-oesophageal reflux disease, but suffer from functional heartburn or dyspepsia. The potential mechanisms underlying failure of PPI treatment in patients with reflux-related symptoms include persistence of isolated or mixed acid, weakly acidic, bile or gas reflux, impaired oesophageal mucosal integrity, chemical or mechanical hypersensitivity to refluxates and psychological comorbidity. After thorough clinical evaluation and failure of empirical changes in PPI dose regime, diagnostic investigations include endoscopy and reflux monitoring with pH or pH-impedance monitoring. If symptoms are clearly related to persistent reflux, baclofen, antireflux surgery or pain modulators can be considered. If not, pain modulators are the only currently available therapy.

show abstract

“…Of the 24 items, 11 articles (61%) met all criteria for economic evaluation reporting [8–15,18,19,21]. Only one did not explicitly identify the study as an economic evaluation in the title [16].…”

Section: Resultsmentioning

confidence: 99%

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

et al. 2014

View full text Add to dashboard Cite

SUMMARY Background Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Aims Our aims were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports and to summarize the economic outcomes of these evaluations. Methods We identified economic evaluations and cost studies of GERD management strategies by searching PUBMED and the NHS economic evaluation database via the Cochrane library. Searching was restricted to articles in English language journals from July 2003 to July 2013. Cost identification articles were excluded from the final analysis. Results Eighteen articles were included in the final analysis; 61% of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high H. pylori prevalence (>40%). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is the most cost-effective initial strategy for patients with typical GERD symptoms. Surgery may be cost-effective in patients with chronic GERD symptoms at time horizons of 3–10 years. Endoscopic anti-reflux procedures were not cost-effective based on available data. Conclusions Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.

show abstract

The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial

Abstract: Esomeprazole was associated with a statistically significant gain in QALMs and was cost effective in primary care patients with persistent acid-related symptoms identified by the PASS test.

Cited by 36 publications

References 19 publications

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors

Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

Contact Info

Product

Resources

About